Two other drug families that were recently approved for treatment of diabetes mellitus are the Glucagone like Peptide-1 (GLP-1) analogues and Di Peptidyl Peptidase IV (DPP4) inhibitors, both act via the incretin pathway. This evidence concerns the gene GCG and diabetes mellitus.